Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Queen Mary University of London |
| Country | United Kingdom |
| Start Date | May 01, 2025 |
| End Date | Oct 31, 2026 |
| Duration | 548 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 101189457 |
Advances in stem cell technologies have revolutionised cell therapy and advanced in vitro models, but remain limited by our ability to scale up and automate cell manufacturing.
In particular, induced pluripotent stem cell (iPSC) expansion and differentiation require complex processing protocols that are preventing the wider deployment of associated technologies to the clinic and industry.
Although solid and hydrogel microcarriers have displayed potential in addressing this challenge, they present hurdles to the processing and separation from cell products, leading to contamination of the generated cells, the poor control of their phenotype and high production costs.
Developing cost-effective, scalable, and regulatory-compliant platforms for culturing, differentiating and processing iPSCs, while circumventing reliance on solid substrates and microcarriers, remains critical for advancing cell manufacturing and will significantly impact the sustained growth of associated biotech markets.
To mitigate contamination risks, streamline bioprocessing, and reduce associated costs, bioemulsions have emerged as promising alternatives.
Despite their demonstrated performance in a growing range of cellular contexts, current underpinning protein and polymer nanosheet technologies raise concerns regarding regulatory compliance, for broad application in regenerative medicine.
We propose the engineering of recombinant protein nanosheets for the stabilisation of biomedical grade oil microdroplets, that will tackle these challenges and allow the production of bioemulsions in a scalable format, aligned with regulatory expectations.
The ability of the resulting bioemulsions to sustain the culture of iPSCs and their differentiation into defined lineages will be validated and this technology will be de-risked, in collaboration with industrial partners aiming to scale up iPSC technologies. This will allow the development of further IP that will support the exploitation of bioemulsions.
Queen Mary University of London
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant